Tracers / [89Zr]DFO-NY003/
[89Zr]DFO-NY003/
Also written as [Zr-89]Zr-DFO-NY003/
- Radionuclide
- Zr-89 t½ 4704 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- DFO-conjugated anti-TROP-2 antibody
- Target / mechanism
- TROP-2 (trophoblast cell-surface antigen-2) PMID 38194043
- Clinical application
- ImmunoPET imaging and radioimmunotherapy theranostic pair for TROP-2 positive triple-negative breast cancer PMID 38194043
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| SmartModule X | custom manifold | SPE | 56% no | more than 99% | DFO-Bz-NCS-NY003 | 38194043 2024 EJNMMI Radiopharm Chem A self-designed radiolabelling module (SmartModule X) was employed for radiochemical synthesis. — The non-decay-corrected radiochemical yields of [89Zr]Zr-DFO-NY003 and [177Lu]Lu-DTPA-NY003 were 56% and 96%, respectively. |
Need this precursor?We can point you to suppliers for [89Zr]DFO-NY003/, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38194043. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 38194043: 'Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model.'.